Activity of Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxohexanoic acid) against human respiratory viruses in in vivo experiments

Pharmaceuticals

Volumn 4, Issue 12, 2011, Pages 1518-1534

  Zarubaev, Vladimir V ^a   Garshinina, Angelica V ^a   Kalinina, Nelly A ^a   Shtro, Anna A ^a   Belyaevskaya, Svetlana V ^a   Slita, Alexander V ^a   Nebolsin, Vladimir E ^b   Kiselev, Oleg I ^a  

^a Influenza Research Institute   (Russian Federation)

^b ValentaPharm Ltd   (Russian Federation)

Author keywords

Adenovirus; Animal model; Antiviral; Influenza; Ingavirin; Pandemic; Parainfluenza virus

Indexed keywords

ANTIVIRUS AGENT; INGAVIRIN; OSELTAMIVIR; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN ADENOVIRUS INFECTION; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOLECULAR WEIGHT; MORTALITY; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS INFECTION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS LOAD; WEIGHT REDUCTION;

EID: 84855257681     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4121518     Document Type: Article

References (45)

1. World Health Organization (WHO), CSR, Disease Outbreak News [abbreviated and edited]. Available online: http://www.who.int/csr/don/2010_05_21/en/index.html (accessed on 11 November 2011).
2. Moscona, A. Oseltamivir resistance-Disabling our influenza defenses. N. Engl. J. Med. 2005, 353, 2633-2636.
3. Moscona, A. Medical management of influenza infection. Annu. Rev. Med. 2008, 59, 397-413.
4. Hayden, F.G. Combination antiviral therapy for respiratory virus infections. Antivir. Res. 1996, 29, 45-48.
5. CDC. Influenza activity-United States and worldwide, May 18-September 19. MMWR Morb. Mortal. Wkly. Rep. 2008, 57, 1046-1049.
6. Dawood, F.S.; Jain, S.; Finelli, L.; Shaw, M.W.; Lindstrom, S.; Garten, R.J.; Gubareva, L.V.; Xu, X.; Bridges, C.B.; Uyeki, T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360, 2605-2615.
7. Hayden, F. Developing new antiviral agents for influenza treatment: What does the future hold? Clin. Infect. Dis. 2009, 1, 3-13.
8. Hauge, S.H.; Dudman, S.; Borgen, K.; Lackenby, A.; Hungnes, O. Oseltamivir-resistant influenza viruses A (H1N1), Norway. Emerg. Infect. Dis. 2007, 15, 155-162.
9. Dharan, N.J.; Gubareva, L.V.; Meyer, J.J.; Okomo-Adhiambo, M.; McClinton, R.C.; Marshall, S.A.; St, G.K.; Epperson, S.; Brammer, L.; Klimov, A.I.; et al. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. J. Am. Med. Assoc. 2009, 301, 1034-1041.
10. Chan, P.A.; Connell, N.T.; Gabonay, A.M.; Westley, B.; Larkin, J.M.; Larosa, S.P.; Chapin, K.; Mermel, L. Oseltamivir resistant 2009-2010 pandemic influenza A (H1N1) in an immunocompromised patient. Clin. Microbiol. Infect. 2010, 16, 1576-1578.
11. Abed, Y.; Boivin, G. Treatment of respiratory virus infections. Antivir. Res. 2006, 70, 1-16.
12. Greenough, A. Respiratory syncycial virus infections: Clinical features, management and prophylaxis. Curr. Opin. Pulm. Med. 2002, 8, 214-217.
13. Henrickson, K.J. Parainfluenza viruses. Clin. Microbiol. Rev. 2003, 16, 242-264.
14. Balfour, H.H. Antiviral drugs. N. Engl. J. Med. 1999, 340, 1255-1268.
15. Loginova, Sia.; Borisevich, S.V.; Maksimov, V.A.; Bondarev, V.P.; Nebol'sin, V.E. Therapeutic efficacy of Ingavirin, a new domestic formulation against influenza A virus (H3N2). Antibiot. Khimioter. 2008, 53, 27-30.
16. Zarubaev, V.V.; Garshinina, A.V.; Kalinina, N.A.; Shtro, A.A.; Nebol'sin, V.E.; Kiselev, O.I. Antiviral activity of Ingavirin in experimental lethal influenza due to influenza virus B in albino mice. Antibiot. Khimioter. 2010, 55, 8-11.
17. Loginova, S.I.; Borisevich, S.V.; Lykov, M.V.; Vedenina, E.V.; Borisevich, G.V.; Bondarev, V.P.; Nebol'sin, V.E.; Chuchalin, A.G. In vitro efficacy of ingavirin against the Mexican pandemic subtype H1N1 of influenza A virus, strains A/California/04/2009 and A/California/07/2009. Antibiot. Khimioter. 2009, 54, 15-17.
18. Zarubaev, V.V.; Garshinina, A.V.; Kalinina, N.A.; Shtro, A.A.; Beliaevskaia, S.V.; Nebol'sin, V.E.; Kiselev, O.I. Protective activity of Ingavirin in experimental lethal influenza due to pandemic influenza virus A (H1N1)v in albino mice. Antibiot. Khimioter. 2010, 55, 24-31.
19. Shishkina, L.N.; Nebolsin, V.E.; Kabanov, A.S.; Skarnovich, M.O.; Mazurkova, N.A.; Sergeev, A.A.; Serova, O.A.; Stavsky, E.A.; Drozdov, L.G. In vitro and in vivo efficacy of Ingavirin against strains of pandemic influenza virus A(H1N1/09)V. Zh. Mikrobiol. Epidemiol. Immunobiol. 2011, 93-96.
20. Zarubaev, V.V.; Krivitskaia, V.Z.; Nebol'sin, V.E.; Kiselev, O.I. Experimental investigation of Ingavirin antiviral activity against human parainfluenza virus. Antibiot. Khimioter. 2010, 55, 13-6.
21. Zarubaev, V.V.; Slita, A.V.; Sirotkin, A.C.; Nebol'sin, V.E.; Kiselev, O.I. Experimental investigation of Ingavirin antiviral activity against human adenovirus. Antibiot. Khimioter. 2010, 55, 19-24.
22. Narasaraju, T.; Sim, M.K.; Ng, H.H.; Phoon, M.C.; Shanker, N.; Lal, S.K.; Chow, V.T. Adaptation of human influenza H3N2 virus in a mouse pneumonitis model: Insights into viral virulence, tissue tropism and host pathogenesis. Microbes Infect. 2009, 11, 2-11.
23. Reed, L.J.; Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 1938, 27, 493-497.
24. Greer, C.E.; Zhou, F.; Goodsell, A.; Legg H.S.; Tang, Z.; zur Megede, J.; Uematsu, Y.; Polo, J.M.; Vajdy, M. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. Scand. J. Immunol. 2007, 66, 645-653.
25. Zarubaev, V.V.; Slita, A.V.; Sukhinin, V.P.; Nosach, L.N.; Dyachenko, N.S.; Povnitsa, O.Y.; Zhovnovataya, V.L.; Alexeeva, I.V.; Palchikovskaya, L.I. Effect of 6-azacytidine on the course of experimental adenoviral infection in newborn Syrian hamsters. J. Chemother. 2007, 19, 44-51.
26. Krug, R.M.; Aramini, J.M. Emerging antiviral targets for influenza A virus. Trends Pharmacol. Sci. 2009, 30, 269-277.
27. Semenova, N.P.; Prokudina, E.N.; L'vov, D.K.; Nebolsin, V.E. Effect of the antiviral drug Ingavirin on intracellular transformations and import into the nucleus of influenza A virus nucleocapsid protein. Vopr. Virusol. 2010, 55, 17-20.
28. Hagiwara, K.; Kondoh, Y.; Ueda, A.; Yamada, K.; Goto, H.; Watanabe, T.; Nakata, T.; Osada, H.; Aida, Y. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem. Biophys. Res. Commun. 2010, 394, 721-727.
29. Kao, R.Y.; Yang, D.; Lau, L.S.; Tsui, W.H.; Hu, L.; Dai, J.; Chan, M.P.; Chan, C.M.; Wang, P.; Zheng, B.J.; et al. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol. 2010, 28, 600-605.
30. Zarubaev, V.V.; Belyaevskaya, S.V.; Sirotkin, A.C.; Anfimov, P.M; Nebol'sin, V.E.; Kiselev, O.I.; Reikhart, D.V. Effect of Ingavirin on ultrastructure and infectivity of influenza virus in vitro and in vivo. Vopr. Virusol. 2011, 56, 21-25.
31. Smee, D.F.; Hurst, B.L.; Wong, M.H.; Tarbet, E.B.; Babu, Y.S.; Klumpp, K.; Morrey, J.D. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antivir. Res. 2010, 88, 38-44.
32. Zambon, M.C. Epidemiology and pathogenesis of influenza. J. Antimicrob. Chemother. 1999, 44S, 3-9.
33. Lapinsky, S.E. Epidemic viral pneumonia. Curr. Opin. Infect. Dis. 2010, 23, 139-144.
34. Rello, J.; Rodríguez, A.; Ibañez, P.; Socias, L.; Cebrian, J.; Marques, A.; Guerrero, J.; Ruiz-Santana, S.; Marquez, E.; Del Nogal-Saez, F.; et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit. Care 2009, 13, R148:1-R148:9.
35. Woo, P.C.; Tung, E.T.; Chan, K.H.; Lau, C.C.; Lau, S.K.; Yuen, K.Y. Cytokine profiles induced by the novel swine-origin influenza A/H1N1 virus: Implications for treatment strategies. J. Infect. Dis. 2010, 201, 346-353.
36. Garigliany, M.M.; Habyarimana, A.; Lambrecht, B.; van de Paar, E.; Cornet, A.; van den Berg, T.; Desmecht, D. Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg. Infect. Dis. 2010, 16, 595-603.
37. To, K.K.; Hung, I.F.; Li, I.W.; Lee, K.L.; Koo, C.K.; Yan, W.W.; Liu, R.; Ho, K.Y.; Chu, K.H.; Watt, C.L.; et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin. Infect. Dis. 2010, 50, 850-859.
38. Schmitz, N.; Kurrer, M.; Bachmann, M.F.; Kopf, M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 2005, 79, 6441-6448.
39. Dawson, T.C.; Beck, M.A.; Kuziel, W.A.; Henderson, F.; Maeda, N. Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am. J. Pathol. 2000, 156, 1951-1959.
40. Carey, M.A.; Bradbury, J.A.; Seubert, J.M.; Langenbach, R.; Zeldin, D.C.; Germolec, D.R. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol. 2005, 175, 6878-6884.
41. Alleva, L.M.; Cai, C.; Clark, I.A. Using Complementary and alternative medicines to target the host response during severe influenza. Evid. Based Complement. Alternat. Med. 2010, 7, 501-510.
42. Kurokawa, M.; Watanabe, W.; Shimizu, T.; Sawamura, R.; Shiraki, K. Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice. Antivir. Res. 2010, 85, 373-380.
43. Loginova, S.Y.; Borisevich, S.V.; Maksimov, V.A.; Bondarev, V.P. Toxicity estimation of unspecific medicinal antiviral agents for prophylaxis and therapy of hazard and especially hazard viral infections. Antibiot. Khimioter. 2009, 54, 3-4.
44. Tamiflu safety data sheet. Available online: http://www.drugbank.ca/system/msds/DB00198.pdf?1265922744/ (accessed on 11 November 2011).
45. Kolobukhina, L.V.; Merkulova, L.N.; Shchelkanov, M.Iu.; Burtseva, E.I.; Isaeva, E.I.; Malyshev, N.A.; L'vov, D.K. Efficacy of ingavirin in adults with influenza. Ter. Arkh. 2009, 81, 51-54.